bremazocine and Disease Models, Animal

bremazocine has been researched along with Disease Models, Animal in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dortch-Carnes, J; Potter, DE	1
da Fonseca Pacheco, CM; da Fonseca Pacheco, D; de Castro Perez, A; de Francischi, JN; Duarte, ID; Klein, A	1
Fowler, CJ; Tiger, G	1

Reviews

1 review(s) available for bremazocine and Disease Models, Animal

Article	Year
Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS drug reviews, 2005,Summer, Volume: 11, Issue:2 Topics: Analgesics; Animals; Benzomorphans; Cardiovascular System; Disease Models, Animal; Diuresis; Humans; Motor Activity; Pain; Receptors, Opioid, kappa; Respiration; Signal Transduction; Synaptic Transmission	2005

Other Studies

2 other study(ies) available for bremazocine and Disease Models, Animal

Article	Year
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. British journal of pharmacology, 2008, Volume: 154, Issue:5 Topics: Amidohydrolases; Analgesics, Opioid; Animals; Arachidonic Acids; Benzamides; Benzomorphans; Cannabinoid Receptor Modulators; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hyperalgesia; Indoles; Male; Morphine; Organophosphonates; Pain; Pain Measurement; Piperazines; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu	2008
Comparison of the effects of a series of kappa-opioid receptor agonists upon sodium channel function in rat brain miniprisms. Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology, 1997, Volume: 117, Issue:1 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Benzeneacetamides; Benzomorphans; Brain; Disease Models, Animal; Inositol Phosphates; Naloxone; Pyrrolidines; Rats; Receptors, Opioid, kappa; Sodium Channels	1997

Article

Year

The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.

British journal of pharmacology, 2008, Volume: 154, Issue:5

Topics: Amidohydrolases; Analgesics, Opioid; Animals; Arachidonic Acids; Benzamides; Benzomorphans; Cannabinoid Receptor Modulators; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hyperalgesia; Indoles; Male; Morphine; Organophosphonates; Pain; Pain Measurement; Piperazines; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu

2008

Comparison of the effects of a series of kappa-opioid receptor agonists upon sodium channel function in rat brain miniprisms.

Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology, 1997, Volume: 117, Issue:1

Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Benzeneacetamides; Benzomorphans; Brain; Disease Models, Animal; Inositol Phosphates; Naloxone; Pyrrolidines; Rats; Receptors, Opioid, kappa; Sodium Channels

1997